Novartis withdraws imatinib NDA for PAH
13:11 EDT 17 Aug 2012 | BioCentury
Novartis AG (NYSE:NVS; SIX:NOVN) withdrew an NDA for imatinib to treat pulmonary arterial hypertension (PAH) after FDA told the company additional data would be needed to support approval. The agency subsequently cancelled the Sept. 14 meeting of the..
Original Article: Novartis withdraws imatinib NDA for PAH
More From BioPortfolio on "Novartis withdraws imatinib NDA for PAH"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
